SCHEMBL5611432

SCHEMBL5611432

O=C(Nc1cc(Br)c(F)cc1F)Nc1cccc2c1ccn2Cc1ccncc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
POLB P06746 1/20 0.40
EPHB4 P54760 3/20 0.38
HTT P42858 1/20 0.38
FGFR1 P11362 3/20 0.38
FGFR4 P22455 3/20 0.38
TRPV1 Q8NER1 4/20 0.38
USP2 O75604 1/20 0.36
MAPK10 P53779 1/20 0.36
KDR P35968 1/20 0.36
TEK Q02763 1/20 0.36
PTGER3 P43115 1/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5586067 0.89 NAMPT (0.44) THRATHRBEPHB4HTTTRPV1
SCHEMBL5612143 0.83 EPHB4 (0.52) EPHB4TRPV1KDRTEKPTGER3
SCHEMBL5592847 0.82 MEN1 (0.56) HTTTRPV1KDRALDH1A1
SCHEMBL5602128 0.81 CCNC (0.44) THRATHRBEPHB4TRPV1PTGER3
SCHEMBL5611827 0.81 EPHB4 (0.45) THRATHRBEPHB4USP2MAPK10
SCHEMBL5592628 0.80 ERBB4 (0.43) THRATHRBEPHB4KDRTEK
SCHEMBL5592676 0.79 EPHB4 (0.52) EPHB4FGFR1TRPV1KDRTEK
SCHEMBL12028947 0.79 THRA (0.44) THRATHRBEPHB4PTGER3KDM4E
SCHEMBL5612270 0.79 MAPT (0.48) POLBEPHB4HTTUSP2KDR
SCHEMBL5585843 0.78 EPHB4 (0.52) THRATHRBEPHB4HTTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP claimed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US claimed
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP disclosed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US disclosed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity UCK2, CHUK, AXL THRA 2643/4885THRB 3212/4885POLB 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.